Elanco Animal Health Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining us. My name is Nathan Rich, and I cover the animal health space here at Goldman. We're very pleased to introduce our next session with Elanco Animal Health. We're joined by the company's President and CEO, Jeff Simmons.
Before we jump into the Q&A, I just wanted to remind everyone on the webcast (Operator Instructions)
And with that, Jeff, thanks so much for your time, and thanks for joining us today.
Questions & Answers
Maybe to start at a high level, if you could just summarize for investors, the company's in December issued guidance for 3% to 4% annual revenue growth and working towards an EBITDA margin of 31% by 2024. If achieved, that would significantly improve the company's financial profile over the next 3 years.
I guess to start, what are the key priorities, in your view, that the business needs
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |